The schistosomiasis market reached a value of USD 53.5 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 74.1 Million by 2035, exhibiting a growth rate (CAGR) of 3.01% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2024
|
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 53.5 Million |
Market Forecast in 2035
|
USD 74.1 Million |
Market Growth Rate (2025-2035)
|
3.01% |
The schistosomiasis market has been comprehensively analyzed in IMARC's new report titled "Schistosomiasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Schistosomiasis, also referred to as bilharzia, is a parasitic ailment caused by infection with blood fluke worms of the genus Schistosoma. In the early acute stage, patients may experience fever, chills, headaches, muscle aches, and a skin rash known as "swimmer's itch" from the penetration of cercariae into the skin. As the condition progresses to the chronic stage, symptoms may include diarrhea, abdominal pain, blood in the urine or stool, liver and spleen enlargement, fatigue, etc. In cases of urogenital schistosomiasis, there can be bladder and urinary tract complications, such as painful urination and an increased likelihood of urinary tract infections. During the clinical evaluation, healthcare providers inquire about symptoms, exposure to freshwater sources, and travel history to endemic regions. Numerous laboratory procedures, including the examination of stool or urine samples for the presence of parasite eggs using microscopic techniques, are performed. For more sensitive and specific diagnostics, rapid diagnostic tests (RDTs) that detect schistosome antigens in blood or urine are increasingly used. In cases of suspected organ involvement, various imaging studies, including ultrasound or computed tomography (CT) scans, help in revealing evidence of tissue damage or enlargement of organs.
The increasing cases of contact with contaminated water, through which the parasitic worms penetrate the skin and enter the bloodstream, initiating the infection, are primarily driving the schistosomiasis market. Furthermore, the inflating application of praziquantel that works by paralyzing and killing the adult worms, which are then expelled from the body through urine or feces, is creating a positive outlook for the market. Apart from this, the widespread adoption of host-directed therapies, since they aid in minimizing inflammation and tissue damage caused by the parasite, thus reducing the symptoms associated with the condition and improving treatment outcomes, is also bolstering the market growth. Moreover, various key players are making extensive investments in R&D activities to introduce vaccines that target several schistosome antigens to stimulate protective immune responses and alleviate reinfection rates, thereby potentially limiting disease severity. This, in turn, is further acting as another significant growth-inducing factor. Additionally, the ongoing advancements in diagnostic technologies, such as the introduction of loop-mediated isothermal amplification (LAMP), that can detect low parasite loads with high sensitivity and offer improved accuracy, are expected to drive the schistosomiasis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the schistosomiasis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for schistosomiasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the schistosomiasis market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current schistosomiasis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Biltricide (Praziquantel) | Bayer AG |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Schistosomiasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies